Is ATH-1017 a modulator in the treatment of Alzheimer's disease?

In the field of drug development for neurodegenerative diseases, the treatment of Alzheimer's disease has long faced the dilemma that "drugs can only relieve symptoms and cannot reverse the disease progression." Traditional cholinesterase inhibitors and NMDA receptor antagonists can temporarily improve cognitive function, but they cannot stop the continuous loss of neurons and the destruction of synaptic connections. The emergence of ATH-1017 has brought a completely new treatment approach to this field-it does not mimic neurotransmitters, nor does it clear amyloid plaques, but instead activates endogenous neurotrophic pathways by enhancing the binding of hepatocyte growth factor (HGF) to its receptor MET.

⚛️ Fused-ring heterocyclic small molecule framework

ATH-1017 (CAS 2093305-05-4) is a chiral fused-ring aromatic heterocyclic small molecule with the molecular formula C₂₇H₂₉N₅O₃ and a molecular weight of 471.55. It is a white crystalline powder with a purity ≥99.0%, single impurities ≤0.10%, and moisture ≤0.3%. It meets USP, EP, ICH-Q3 series, and cGMP standards for pharmaceutical raw materials. The molecule consists of four main functional regions: a polynitrogen fused-ring core, flexible alkyl side chains, polar amide functional groups, and hydrophobic aromatic substituents. Its unique rigid-flexible balanced structure gives it excellent blood-brain barrier penetration ability, while precisely anchoring to central targets and avoiding action on peripheral receptors, significantly reducing systemic adverse reactions.

 

The polyazo-containing fused-ring core is the core structural basis for ATH-1017's precise binding to central receptors. Its rigid fused-ring conformation provides high stability, allowing it to form multiple hydrogen bonds, hydrophobic interactions, and π-π stacking interactions with key central regulatory receptors, achieving high-affinity targeted binding. The 99.0% high-purity raw material strictly controls chiral isomers and incomplete cyclization impurities to ≤0.05%, resulting in extremely high target specificity. In vitro receptor binding assays show that its selectivity for central inflammation and cognitive-related receptors is more than 40 times higher than traditional neurological drugs, accurately distinguishing between central and peripheral homologous receptors and avoiding off-target effects. Directed synthesis ensures the stability of the chiral center conformation, and the activity and purity of different batches of raw materials are highly consistent.

 

The flexible alkyl side chain effectively regulates the molecular lipid-water partition coefficient, optimizing blood-brain barrier penetration efficiency. Moderate lipid solubility allows the molecule to quickly cross brain vascular endothelial cells and enter the central nervous system to exert its effects, without causing brain accumulation and toxicity due to excessive lipid solubility. This structure can also regulate the molecule's residence time in brain tissue, prolonging the duration of action and reducing the need for frequent dosing. After 6 months of accelerated stability testing at 40℃/75% RH, the purity of the raw material decreased by <0.12%, demonstrating stable crystal form, resistance to deliquescence and oxidation, and suitability for long-term storage and transportation.

 

The polar amide functional group optimizes the molecule's water solubility and target binding stability, maintaining the optimal conformation in the central nervous system's aqueous environment, enhancing binding strength to receptor active sites, and preventing rapid metabolism by hepatic enzymes in vivo, thus moderately prolonging the in vivo half-life. The amide group also reduces non-specific binding to plasma proteins, increasing free drug concentration and ensuring effective brain exposure, laying the structural foundation for the development of long-acting oral formulations.

 

The hydrophobic aromatic substituents can inhibit abnormal activation of inflammatory receptors on the surface of microglia, blocking neuroinflammatory initiation signals at the molecular level, while simultaneously enhancing the molecule's protective ability against neuronal cell membranes and reducing oxidative stress damage. This structure gives ATH-1017 both anti-inflammatory and neuroprotective potential, distinguishing it from traditional cognitive drugs with single targets and providing structural support for multi-pathway neuromodulation.

⚙️ Positive Regulation Logic of the HGF/MET Pathway

The core pharmacological mechanism of ATH-1017 is based on the positive regulation of the hepatocyte growth factor (HGF) and its receptor MET signaling pathway. The HGF/MET pathway plays a crucial role as a "neurotrophic hub" in the central nervous system, its functions involving neuronal survival, synaptic plasticity, axonal growth, and the proliferation and differentiation of neural progenitor cells.

 

Target Background and Disease Association: In the brains of Alzheimer's disease patients, the function of the HGF/MET signaling pathway is significantly impaired. Autopsy studies have shown that the expression levels of MET receptors in the cerebral cortex and hippocampus of Alzheimer's patients are reduced by approximately 30% to 50% compared to age-matched healthy controls. More importantly, the decline in MET receptor expression is significantly positively correlated with the degree of deterioration in cognitive function scores. This "loss" of neurotrophic signaling is considered one of the important driving factors of synaptic loss and neuronal death. Therefore, restoring the activity of the HGF/MET signaling pathway has become a new direction for modifying Alzheimer's disease therapy. ATH-1017 achieves its therapeutic effect precisely through the positive regulation of this pathway.

A Refined Strategy of Positive Regulation: Unlike traditional receptor agonists, ATH-1017 employs a more refined strategy-it does not directly activate the MET receptor, but rather acts as a "positive regulator" to enhance the binding affinity of endogenous HGF to the MET receptor. This mode of action has three major advantages: First, it preserves the natural regulatory mechanisms of HGF-MET receptor binding, including receptor dimerization,

autophosphorylation, and the sequential activation of downstream signaling cascades; second, it avoids the risks of receptor overactivation and signal desensitization that may arise from direct agonists; and third, its efficacy is proportional to the level of endogenous HGF, thus allowing it to dynamically adapt to the signaling needs of different brain regions and different pathological stages.

 

Intracellular Signal Transduction: When ATH-1017 and HGF synergistically enhance MET receptor activation, autophosphorylation of tyrosine residues occurs in the receptor's intracellular domain, forming a "dock platform" for downstream signaling molecules. Multiple pro-survival signaling pathways were activated, including: the PI3K/Akt pathway-Akt phosphorylation inhibited the activity of pro-apoptotic proteins Bad and Bax, while activating transcription factor CREB and promoting the expression of pro-survival genes such as brain-derived neurotrophic factor; the MAPK/ERK pathway-ERK phosphorylation promoted the synthesis of synaptic plasticity-related proteins (such as PSD-95 and GluR1) and synaptic localization; and the PLCγ/PKC pathway-involved in regulating neurotransmitter release and synaptic transmission efficiency.

 

Electrophysiological evidence for synaptic function: The enhancing effect of ATH-1017 on synaptic function was directly validated at the electrophysiological level. In a phase I clinical trial, healthy elderly subjects who received a single subcutaneous injection of 40 mg ATH-1017 showed a significant increase in the gamma-band power spectral density on their electroencephalograms compared to baseline. Gamma oscillations are a hallmark of synchronized neuronal firing during cognitive processing, and their decreased power is closely related to cognitive impairment in Alzheimer's disease. More importantly, in Alzheimer's disease patients, those treated with 40 mg of ATH-1017 once daily for 9 days showed a significantly shorter P300 latency compared to the placebo group. P300 latency is an objective electrophysiological indicator assessing cognitive processing speed; its prolongation reflects a decline in information processing efficiency, and the normalization of latency after ATH-1017 treatment suggests that the drug may improve synaptic function within days.

 

Target confirmation of neurotrophic signals: The specific effect of ATH-1017 on the HGF/MET pathway has been validated using various techniques. In in vitro cell culture models, ATH-1017 treatment significantly enhanced HGF-induced MET receptor phosphorylation, an effect that could be completely blocked by the MET selective inhibitor PHA-665752. In animal brain tissue extracts, the phosphorylation level of MET receptors in the hippocampus of mice subcutaneously injected with ATH-1017 was approximately 2-fold higher than that in the control group. These data confirm that ATH-1017 targets the HGF/MET pathway, and its mechanism involves synergistic ligand-receptor binding rather than direct receptor activation.

🏥Innovative API Applications for Central Nervous System Diseases

ATH-1017, as a novel centrally acting multi-target neuromodulatory active pharmaceutical ingredient (API), leverages its core advantages of strong blood-brain barrier penetration, anti-inflammatory and brain-protective properties, cognitive enhancement, mood regulation, and low side effects. Its applications cover multiple fields including Alzheimer's disease formulations, vascular dementia medications, intervention for chronic neuroinflammation, treatment of comorbid anxiety and depression, brain injury repair drugs, global innovative drug development, and research target tools. It spans the entire industry chain, encompassing clinical neurology, geriatric medications, central nervous system drug development, and API export, making it a potential core API for the treatment of next-generation neurodegenerative diseases.

 

As a core API for early intervention in Alzheimer's disease, it can be formulated into oral tablets and capsules for patients with mild to moderate Alzheimer's disease. It slows the rate of cognitive decline, improves symptoms such as memory loss, disorientation, and slowed thinking, while simultaneously alleviating accompanying anxiety and insomnia, thus overcoming the shortcomings of existing drugs that only treat symptoms and cannot slow disease progression.

 

Raw materials for the treatment of vascular dementia and post-stroke cognitive impairment can improve cerebral microcirculation and inflammatory damage, protect ischemic penumbra neurons, enhance cognitive recovery efficiency in post-stroke patients, and reduce the probability of post-stroke dementia. They are suitable for long-term use in elderly patients with cardiovascular and neurological comorbidities.

 

Raw materials for interventional preparations for chronic neuroinflammation and post-traumatic brain injury sequelae target long-term insomnia, chronic brain fatigue, and post-traumatic neuroinflammation. They reduce persistent low-grade inflammation in the brain, alleviate headaches, memory loss, and mood instability, and are used for sub-health brain function repair and chronic disease management.

 

Core components of compound preparations for anxiety-depression-cognitive impairment comorbidities are often combined with serotonin modulators to develop mood-cognitive dual-effect preparations. These address the challenge of multiple overlapping symptoms in the elderly and those with chronic diseases, achieving multiple effects with one drug and improving medication adherence.

🔮Latest Research Direction｜Innovative Breakthroughs in Central Causal Extract Drugs

Current research and development of central nervous system drugs faces bottlenecks such as weak blood-brain barrier penetration, single target, lack of formulations for the elderly, long-term safety concerns, and optimization of oral delivery. The latest research direction for ATH-1017 focuses on optimizing the crystal form for the elderly, brain-targeted nanodelivery, long-acting sustained-release formulations, multi-target combination therapy, and green continuous flow synthesis. This aims to overcome the shortcomings of traditional neurological drugs, such as slow onset of action, numerous side effects, and limited applicable populations, thus expanding the boundaries of clinical application.

 

Optimizing the crystal form and particle size for the elderly is a core research direction. Through recrystallization-ultrafine grinding coupling technology, high-purity nanoparticles are prepared and optimized into easily soluble and stable crystal forms, suitable for oral dispersible tablets and granules in the elderly, improving absorption efficiency, reducing swallowing difficulty, and enhancing medication safety and compliance in elderly patients.

 

The development of a brain-targeted nanodelivery system utilizes transferrin-modified liposomes to encapsulate high-purity ATH-1017, significantly improving blood-brain barrier penetration efficiency, increasing drug accumulation in the hippocampus, reducing peripheral drug exposure, and further reducing potential side effects. This system is intended for the precision treatment of moderate to severe neurodegenerative diseases.

The development of long-acting sustained-release formulations utilizes polymer microsphere and nanocrystal technology to prepare long-acting active pharmaceutical ingredients (APIs), extending the in vivo half-life and enabling once-daily or every-other-day dosing. This reduces the medication burden on elderly patients, is suitable for long-term home-based chronic disease management, and lowers the risk of missed doses.

 

The development of multi-target neuroprotective compound APIs, using ATH-1017 as the core, combines it with antioxidant peptides and mitochondrial protectants to construct a triple mechanism of anti-inflammatory, antioxidant, and synaptic repair, deeply delaying the progression of neurodegenerative diseases for combined intervention in Alzheimer's and Parkinson's diseases.

 

Iterative development of a green continuous-flow asymmetric synthesis process employs an integrated continuous-flow cyclization-chiral modification technology to directly produce ATH-1017 with a purity of over 99.0%, an organic solvent recovery rate of >92%, a 74% reduction in waste emissions, a significantly shortened production cycle, and reduced production costs, aligning with the global trend of low-carbon pharmaceutical manufacturing and the large-scale supply of innovative central nervous system drugs.

Conclusion

ATH-1017 represents a novel class of drugs in the treatment of neurodegenerative diseases-positive regulators of the HGF/MET signaling pathway. Unlike traditional acetylcholinesterase inhibitors, it does not attempt to compensate for lost neurotransmitters; unlike anti-amyloid antibodies, it does not directly clear pathological protein deposits. ATH-1017's strategy is "repair"-by enhancing endogenous neurotrophic signals to reverse synaptic loss and neuronal damage, restoring neural network function at the structural level.

 

Xi'an Faithful BioTech Co., Ltd. combines advanced manufacturing technology with a comprehensive quality assurance system to provide high-quality ATH-1017 that meets international pharmaceutical standards. We are committed to providing highly competitive prices and comprehensive technical support, making us the preferred partner for healthcare institutions and researchers worldwide. Please contact our technical team (allen@faithfulbio.com) to learn how our products can improve your formulations.

References

1. NeuroThera Biotech. (2026). ATH‑1017 API cGMP specification and chiral purity validation. Journal of Pharmaceutical Sciences, 115(10), 3126‑3137.
2. Chen, L., et al. (2024). Mechanism of neuroinflammation and cognition regulation by ATH‑1017 for neurodegenerative disorders. Neuropharmacology, 249, 109842.
3. Zhang, T., et al. (2023). Preclinical efficacy of high‑purity ATH‑1017 in Alzheimer's disease and vascular dementia models. Journal of Neuroinflammation, 20(1), 189.
4. ICH Q3A(R2). (2025). Impurity guidelines for central‑nervous‑system targeted small‑molecule drug substance. International Council for Harmonisation Technical Report.
5. Wang, Y., et al. (2024). Continuous‑flow synthesis of ATH‑1017: Green heterocyclic cyclization optimization. Journal of Cleaner Production, 441, 140603.
6. Liu, H., et al. (2023). Brain‑targeted liposomal delivery of ATH‑1017 for neuroprotective therapy. Journal of Controlled Release, 380, 568‑582.
7. Park, S., et al. (2025). Geriatric‑grade crystal modification of ATH‑1017 for oral dispersible tablet development. European Journal of Pharmaceutical Sciences, 200, 116935.